Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for ...

Anti-VEGF injection followed by dexamethasone intravitreal implant showed noninferior efficacy to conventional treatment regimen.

HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults ...

Breakout Momentum Plays You May Not Know About; Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet ag ...

Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar ...

Researchers have created a powerful new cellular model to study rare tumors that are resistant to immunotherapies.

Steroids, specifically corticosteroids, work by reducing inflammation that puts pressure on nerves and causes back pain. They lower levels of prostaglandins and other chemicals involved in the ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...